Last edition
News about "New Drug Application (NDA) "
US FDA Accepts Gadoquatrane for Review: Bayer
Bayer has submitted New Drug Application (NDA) for low dose contrast agent gadoquatrane to seek approval for contrast-enhanced Magnetic Resonance Imaging (MRI) of the Central Nervous System (CNS) and other body regions for adults and paediatric patients including neonates.
New Drug Application (NDA) | 27/08/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members